Evidence-Based Therapy for Heart Failure

被引:13
作者
Deedwania, Prakash C. [1 ,2 ]
Carbajal, Enrique [2 ]
机构
[1] VA Cent Calif Hlth Care Syst, Cardiol Div IIIC, Fresno, CA 93703 USA
[2] Univ Calif San Francisco, Div Cardiol, Dept Med, Fresno Med Educ Program, Fresno, CA 93703 USA
关键词
Evidence-based therapy; Heart failure; Left ventricular dysfunction; Treatment; LEFT-VENTRICULAR DYSFUNCTION; MORBIDITY; MORTALITY; CARVEDILOL; SURVIVAL; TRIAL;
D O I
10.1016/j.mcna.2012.07.010
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Heart failure (HF) is a major public health problem associated with increased morbidity and mortality. As the US life expectancy increases and the population ages, the overall prevalence of HF will continue to escalate. The increasing use of effective selective therapies such as neurohormonal blockade in the treatment of patients with HF has led to considerable improvement in the prognosis. During the past several decades, some studies have demonstrated the benefits of treatment; based on the evidence available from these studies, various national and international guidelines have specific recommendations for the evidence-based therapy with these drugs in patients with HF.
引用
收藏
页码:915 / +
页数:19
相关论文
共 21 条
[1]   THE EFFECT OF THE ANGIOTENSIN-CONVERTING ENZYME-INHIBITOR ZOFENOPRIL ON MORTALITY AND MORBIDITY AFTER ANTERIOR MYOCARDIAL-INFARCTION [J].
AMBROSIONI, E ;
BORGHI, C ;
MAGNANI, B .
NEW ENGLAND JOURNAL OF MEDICINE, 1995, 332 (02) :80-85
[2]  
BALL SG, 1993, LANCET, V342, P821
[3]  
Chakeabarti S, 2010, J CARD FAIL, V16, pS53, DOI 10.1016/j.cardfail.2010.04.004
[4]  
Eichhorn E, 2001, NEW ENGL J MED, V344, P1659
[5]   Potential impact of optimal implementation of evidence-based heart failure therapies on mortality [J].
Fonarow, Gregg C. ;
Yancy, Clyde W. ;
Hernandez, Adrian F. ;
Peterson, Eric D. ;
Spertus, John A. ;
Heidenreich, Paul A. .
AMERICAN HEART JOURNAL, 2011, 161 (06) :1024-U244
[6]   Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function intolerant to angiotensin-converting-enzyme inhibitors:: the CHARM-Alternative trial [J].
Granger, CB ;
McMurray, JJV ;
Yusuf, S ;
Held, P ;
Michelson, EL ;
Olofsson, B ;
Östergren, J ;
Pfeffer, MA ;
Swedberg, K .
LANCET, 2003, 362 (9386) :772-776
[7]  
Hjalmarson Å, 1999, LANCET, V353, P2001
[8]   2009 Focused Update Incorporated Into the ACC/AHA 2005 Guidelines for the Diagnosis and Management of Heart Failure in Adults A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines [J].
Hunt, Sharon Ann ;
Abraham, William T. ;
Chin, Marshall H. ;
Feldman, Arthur M. ;
Francis, Gary S. ;
Ganiats, Theodore G. ;
Konstam, Marvin A. ;
Mancini, Donna M. ;
Michl, Keith ;
Oates, John A. ;
Rahko, Peter S. ;
Silver, Marc A. ;
Stevenson, Lynne Warner ;
Yancy, Clyde W. ;
Jessup, Mariell ;
Casey, Donald E. .
CIRCULATION, 2009, 119 (14) :E391-E479
[9]   A CLINICAL-TRIAL OF THE ANGIOTENSIN-CONVERTING-ENZYME INHIBITOR TRANDOLAPRIL IN PATIENTS WITH LEFT-VENTRICULAR DYSFUNCTION AFTER MYOCARDIAL-INFARCTION [J].
KOBER, L ;
TORPPEDERSEN, C ;
CARLSEN, JE ;
BAGGER, H ;
ELIASEN, P ;
LYNGBORG, K ;
VIDEBEK, J ;
COLE, DS ;
AUCLERT, L ;
PAULY, NC ;
ALIOT, E ;
PERSSON, S ;
CAMM, AJ .
NEW ENGLAND JOURNAL OF MEDICINE, 1995, 333 (25) :1670-1676
[10]  
Lechat P, 1999, LANCET, V353, P9